Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
0.860
-0.020 (-2.26%)
At close: Nov 22, 2024, 4:00 PM
0.870
+0.010 (1.16%)
After-hours: Nov 22, 2024, 7:57 PM EST
Processa Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 4.91 | 5.66 | 8.76 | 4.69 | 3.26 | 1.61 | |
Research & Development | 6.88 | 5.8 | 11.49 | 6.88 | 3.17 | 2.32 | |
Operating Expenses | 11.79 | 11.46 | 20.26 | 11.57 | 6.44 | 3.94 | |
Operating Income | -11.79 | -11.46 | -20.26 | -11.57 | -6.44 | -3.94 | |
Interest Expense | - | - | - | - | -0.28 | -0.04 | |
Interest & Investment Income | 0.26 | 0.34 | 0.1 | 0.01 | 0 | 0.01 | |
EBT Excluding Unusual Items | -11.53 | -11.12 | -20.16 | -11.56 | -6.71 | -3.96 | |
Asset Writedown | - | - | -7.27 | - | - | - | |
Other Unusual Items | - | - | - | 0.16 | - | - | |
Pretax Income | -11.53 | -11.12 | -27.42 | -11.96 | -15.41 | -3.96 | |
Income Tax Expense | - | - | - | -0.53 | -1 | -0.6 | |
Net Income | -11.53 | -11.12 | -27.42 | -11.43 | -14.41 | -3.36 | |
Preferred Dividends & Other Adjustments | - | - | - | - | 4.63 | 0.51 | |
Net Income to Common | -11.53 | -11.12 | -27.42 | -11.43 | -19.04 | -3.86 | |
Shares Outstanding (Basic) | 3 | 1 | 1 | 1 | 0 | 0 | |
Shares Outstanding (Diluted) | 3 | 1 | 1 | 1 | 0 | 0 | |
Shares Change (YoY) | 117.51% | 62.83% | 5.16% | 104.27% | 35.72% | 3.63% | |
EPS (Basic) | -4.55 | -8.48 | -34.05 | -14.92 | -50.77 | -13.99 | |
EPS (Diluted) | -4.55 | -8.48 | -34.05 | -14.92 | -50.77 | -13.99 | |
Free Cash Flow | -11.12 | -8.07 | -9.61 | -8.72 | -3.14 | -2.75 | |
Free Cash Flow Per Share | -4.39 | -6.15 | -11.92 | -11.38 | -8.38 | -9.95 | |
EBITDA | -11.79 | -11.46 | -19.47 | -10.78 | -5.63 | -3.13 | |
D&A For EBITDA | 0 | 0 | 0.79 | 0.79 | 0.8 | 0.8 | |
EBIT | -11.79 | -11.46 | -20.26 | -11.57 | -6.44 | -3.94 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.